Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Weekly Ratings as of Dec 8, 2018

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Corporate Logo
Big Money Sentiment decreased to 1.89 in 2018 Q2. It has change of 0.55, from 2018Q1’s 2.44. The ratio is negative due to Dicerna Pharmaceuticals, Inc. positioning: 16 sold and 12 reduced. 35 funds bought holdings and 18 increased holdings. Investors holded 30.68 million in 2018Q1 but now own 36.31 million shares or 18.35% more.
Bancshares Of Mellon stated it has 0% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Bnp Paribas Arbitrage Sa accumulated 1,606 shs or 0% of the stock. Blackrock has invested 0% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Comml Bank Of America Corp De invested in 9,210 shs. Manufacturers Life Insur The invested 0% of its capital in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). 74,272 were accumulated by Citigroup. Aqr Capital Management Ltd Liability stated it has 43,178 shs. Moreover, Amer Int Group Incorporated has 0% invested in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) for 28,932 shs. Moreover, Bailard has 0.04% invested in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) for 49,800 shs. Geode Mgmt Limited Liability Company reported 0% of its capital in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). National Bank Of Montreal Can holds 73,316 shs. Deutsche Financial Bank Ag reported 0% of its capital in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Moreover, Fmr Limited Liability has 0% invested in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) for 1.44 million shs. California Public Employees Retirement Systems invested in 0% or 57,000 shs. 771 were accumulated by Piedmont Invest Advisors Llc.

Dicerna Pharmaceuticals, Inc. registered $12.83 million net activity with 0 buys and 4 insider sales since August 15, 2018. Weissman James B sold $40,268 worth of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) on Wednesday, September 5. 38,341 shs were sold by LANGER DENNIS, worth $613,456.

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Ratings Coverage

Total analysts of 5 have positions in Dicerna Pharmaceuticals (NASDAQ:DRNA) as follows: 5 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since August 9, 2018 according to StockzIntelligence Inc Dicerna Pharmaceuticals has 7 analyst reports. On Thursday, August 9 the firm earned “Buy” rating by Stifel Nicolaus. On Wednesday, August 15 H.C. Wainwright upgraded the shares of DRNA in report to “Buy” rating. The company rating was maintained by Citigroup on Tuesday, October 30. On Tuesday, November 6 the firm earned “Buy” rating by FBR Capital. On Monday, September 17 the firm earned “Neutral” rating by FBR Capital. Listed here are Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) PTs and latest ratings.

28/11/2018 Broker: Leerink Swann Rating: Outperform New Target: $24 Initiates Coverage On
06/11/2018 Broker: FBR Capital Old Rating: Neutral New Rating: Buy Old Target: $13.5 New Target: $21 Upgrade
30/10/2018 Broker: Citigroup Old Rating: Buy New Rating: Buy Old Target: $27 New Target: $30 Maintain
17/09/2018 Broker: FBR Capital Old Rating: Neutral New Rating: Neutral Old Target: $10 New Target: $13.5 Maintain
13/09/2018 Broker: Citigroup Rating: Buy New Target: $27 Initiates Coverage On
15/08/2018 Broker: H.C. Wainwright Old Rating: Neutral New Rating: Buy Upgrade
09/08/2018 Broker: Stifel Nicolaus Old Rating: Buy New Rating: Buy Old Target: $18 New Target: $20 Maintain

DRNA is reaching $12.74 during the last trading session, after decreased 8.74%.Currently Dicerna Pharmaceuticals, Inc. is uptrending after 325.07% change in last December 8, 2017. DRNA has also 393,230 shares volume. DRNA outperformed the S&P 500 by 309.45%.

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for rare, chronic liver, cardiovascular, and viral infectious diseases in the United States and internationally.The firm is worth $799.20 million. The companyÂ’s preclinical stage development programs include DCR-PHXC for the treatment of primary hyperoxaluria type 1; DCR-PCSK9, which targets the PCSK9 gene in the treatment of statin-refractory patients with hypercholesterolemia; and DCR-HBV for the treatment of chronic hepatitis B virus infection, as well as other product candidates for use in the treatment of cardiovascular and chronic liver diseases.Currently it has negative earnings. It has a research collaboration and license agreements with Kyowa Hakko Kirin Co., Ltd.; City of Hope, an academic research and medical center; and Plant Bioscience Limited.

For more Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) news published briefly go to: Stockhouse.com, Seekingalpha.com, Nasdaq.com, Seekingalpha.com or Seekingalpha.com. The titles are as follows: “Leerink Starts Coverage Of Genetic Medicine Stocks: ‘We See Commercial Execution As Increasingly Driving Returns’ – Stockhouse” published on November 28, 2018, “Premarket analyst action – healthcare – Seeking Alpha” on August 15, 2018, “Bluebird Bio Stock May Have Upside of at Least 60 Percent – Nasdaq” with a publish date: September 12, 2018, “Dicerna up 21% on ripple effect from Arrowhead rally – Seeking Alpha” and the last “Marinus Pharmaceuticals among healthcare gainers; Canopy Growth and Aurora Cannabis among losers – Seeking Alpha” with publication date: October 29, 2018.

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.